Comparative Pharmacology
Head-to-head clinical analysis: JANIMINE versus SILENOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANIMINE versus SILENOR.
JANIMINE vs SILENOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Selective histamine H1 receptor antagonist; promotes sleep by antagonizing central histaminergic neurotransmission.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
6 mg orally once daily at bedtime, not to exceed 6 mg/day.
None Documented
None Documented
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Terminal elimination half-life is approximately 10 hours (range 8-15 hours) in healthy adults; prolonged in elderly and hepatic impairment.
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Primarily renal (approximately 60% as unchanged drug and metabolites), with 30% fecal elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant